 The aim of this study is, to compare the relapse rate in chronic HCV patients with genotype 1 or 3 under the combination of standard dose Peg-Interferon alfa-2a PEG-IFN alfa-2a, Ribavirin RBV and Amantadine AMA given for 72 weeks group A, versus the same combination, given for 48 weeks group B in patients who relapsed to previous combination therapy to conventional or pegylated PEG Interferon alfa and Ribavirin. Relapse ist defined as percentage of patients with non-detectable HCV-RNA at end of therapy week 48 GT1 week 24 GT 3 who become HCV-RNA positive during a follow-up period of 24 weeks. 